Sturtevant F M
Biomed Pharmacother. 1984;38(8):371-9.
A recent report by Pike et al. from the U. S. A. concluded on the basis of epidemiologic evidence that an increased risk of breast cancer was manifested by young women who had used combination oral contraceptives (OC) with a high "potency" of progestogen over a prolonged period. This conclusion is criticized in the present article, centering on three cardinal defects in the Pike study: (1) The assigned potencies of OC's are fiction and were derived from out-dated delay-of-menses data; (2) Well-known risk factors for breast cancer were ignored; (3) The method assumed no error of recall of OC brand, dose and duration of use occurring many years before telephone interviews. Noting that others have not been able to confirm these findings, it is concluded that there is no scientific basis for accepting the suggestion of Pike et al.
美国的派克等人最近发表的一份报告基于流行病学证据得出结论，长期使用高效孕激素复方口服避孕药（OC）的年轻女性患乳腺癌的风险增加。本文对这一结论提出了批评，重点围绕派克研究中的三个主要缺陷：（1）口服避孕药的指定效力是虚构的，来源于过时的经期延迟数据；（2）乳腺癌的知名风险因素被忽视了；（3）该方法假定在电话访谈前许多年服用的口服避孕药品牌、剂量和使用时长不存在回忆误差。鉴于其他人未能证实这些发现，得出的结论是，接受派克等人的建议没有科学依据。
